Genetic Technologies Limited (GNTLF) Predicción del precio de las acciones

Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 58 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its EasyDNA brand. The company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm's segments include EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment relates to EasyDNA branded test sales and expenses. The AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType/Corporate: relates to geneType branded test sales and expense, includes corporate charges.